DK2951202T3 - Mage-a1-genkendende bindingsmolekyler med høj aviditet - Google Patents

Mage-a1-genkendende bindingsmolekyler med høj aviditet Download PDF

Info

Publication number
DK2951202T3
DK2951202T3 DK14702238.8T DK14702238T DK2951202T3 DK 2951202 T3 DK2951202 T3 DK 2951202T3 DK 14702238 T DK14702238 T DK 14702238T DK 2951202 T3 DK2951202 T3 DK 2951202T3
Authority
DK
Denmark
Prior art keywords
stomach
binding molecules
high avidity
recognition binding
recognition
Prior art date
Application number
DK14702238.8T
Other languages
Danish (da)
English (en)
Inventor
Thomas Blankenstein
Matthias Obenaus
Catarina Leitao
Original Assignee
Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch filed Critical Max Delbrueck Centrum Fuer Molekulare Medizin Mdc Berlin Buch
Application granted granted Critical
Publication of DK2951202T3 publication Critical patent/DK2951202T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK14702238.8T 2013-01-29 2014-01-29 Mage-a1-genkendende bindingsmolekyler med høj aviditet DK2951202T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13153081 2013-01-29
PCT/EP2014/051726 WO2014118236A2 (en) 2013-01-29 2014-01-29 High avidity antigen recognizing constructs

Publications (1)

Publication Number Publication Date
DK2951202T3 true DK2951202T3 (da) 2020-07-13

Family

ID=47623953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14702238.8T DK2951202T3 (da) 2013-01-29 2014-01-29 Mage-a1-genkendende bindingsmolekyler med høj aviditet

Country Status (13)

Country Link
US (3) US10377808B2 (enExample)
EP (2) EP3747899A3 (enExample)
JP (1) JP6639233B2 (enExample)
CN (1) CN105377886B (enExample)
AU (2) AU2014211454B2 (enExample)
CA (1) CA2899679C (enExample)
DK (1) DK2951202T3 (enExample)
ES (1) ES2804538T3 (enExample)
HU (1) HUE050390T2 (enExample)
PL (1) PL2951202T3 (enExample)
PT (1) PT2951202T (enExample)
SI (1) SI2951202T1 (enExample)
WO (1) WO2014118236A2 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104843A1 (en) 2011-02-06 2012-08-09 Yeda Research And Development Co.Ltd. At The Weizmann Institute Of Science Affinity maturated t cell receptors and use thereof
JP6712261B2 (ja) * 2014-08-04 2020-06-24 フレッド ハッチンソン キャンサー リサーチ センター Wt−1に特異的なt細胞免疫治療
GB201417803D0 (en) 2014-10-08 2014-11-19 Adaptimmune Ltd T cell receptors
EP3067366A1 (en) 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
US12364757B2 (en) * 2015-10-01 2025-07-22 Ospedale San Raffaele S.R.L TCR and uses thereof
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520544D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
CN106749620B (zh) * 2016-03-29 2020-09-25 广东香雪精准医疗技术有限公司 识别mage-a1抗原短肽的t细胞受体
DK3440105T3 (da) * 2016-04-08 2022-06-13 Immunocore Ltd T-cellereceptorer
CN106084042B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗MAGEA1的全分子IgG抗体及其应用
EP3515935A4 (en) * 2016-09-23 2019-09-04 Lion TCR Pte. Ltd. HBV-Antigen specific binding molecules and fragments thereof
DE102016123847B3 (de) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MY192819A (en) * 2016-12-08 2022-09-12 Immatics Biotechnologies Gmbh Novel t cell receptors and immune therapy using the same
CN108250289B (zh) * 2016-12-28 2021-10-08 香雪生命科学技术(广东)有限公司 源自于mage b6的肿瘤抗原短肽
BR112019018863A8 (pt) * 2017-03-15 2023-05-02 Hutchinson Fred Cancer Res Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术(广东)有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
WO2019046818A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
GB2596461B (en) * 2019-02-20 2023-09-27 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
CA3131138A1 (en) 2019-03-06 2020-09-10 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原1(magea1)特異性t細胞受體及其用途
PE20220231A1 (es) 2019-06-25 2022-02-07 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso
EP3997116A1 (en) * 2019-07-09 2022-05-18 Medigene Immunotherapies GmbH Magea10 specific t cell receptors and their use
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
BR112022014623A2 (pt) 2020-02-14 2022-09-13 Jounce Therapeutics Inc Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
JP7781085B2 (ja) * 2020-06-25 2025-12-05 ザ・メソジスト・ホスピタル 抗原特異的t細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法
IL276599A (en) * 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
CN112279908B (zh) * 2020-10-23 2024-03-19 魏放 识别ebv抗原短肽的t细胞受体及其应用
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
AU2022375782A1 (en) 2021-10-28 2024-05-02 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023083864A1 (en) 2021-11-09 2023-05-19 T-Knife Gmbh Methods of selecting a patient for treatment of a mage-a1 positive solid tumor, of predicting whether a patient being diagnosed with mage-a1 positive solid tumor will be responsive to treatment of this tumor and of treating a patient being diagnosed with such a mage-a1 positive solid tumor as well as corresponding pharmaceutical compositions and diagnostic kits
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3237577A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7抑制劑
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
CN114539386B (zh) * 2022-04-27 2022-07-26 恒瑞源正(广州)生物科技有限公司 Mage-a1特异性t细胞受体及其用途
CA3260083A1 (en) 2022-07-01 2024-01-04 Gilead Sciences Inc CD73 COMPOUNDS
CN120476137A (zh) 2022-08-18 2025-08-12 英美偌科有限公司 对mage a4具有特异性的t细胞受体融合蛋白
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
AU2024252725A1 (en) 2023-04-11 2025-11-06 Gilead Sciences, Inc. Kras modulating compounds
CN121079300A (zh) 2023-04-21 2025-12-05 吉利德科学公司 Prmt5抑制剂及其用途
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025027087A1 (en) 2023-07-31 2025-02-06 T-Knife Gmbh A chimeric human cd8 co-receptor, a nucleic acid encoding the chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
WO2025027088A1 (en) 2023-07-31 2025-02-06 T-Knife Gmbh An enhanced chimeric human cd8 co-receptor, a nucleic acid encoding the enhanced chimeric human cd8 co-receptor, corresponding vectors, isolated t-cells transduced with the nucleic acid or corresponding vectors and kits for preparing them, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease
WO2025045752A1 (en) 2023-08-25 2025-03-06 T-Knife Gmbh Chimeric human cd 95 switch receptor, t-cell expressing said receptor together with an engineered t-cell receptor, respective vectors, kits, pharmaceutical compositions and methods for treating a patient having a disease
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025146286A1 (en) 2024-01-04 2025-07-10 Immunoscape Pte. Ltd. Human t cell receptors and uses thereof
WO2025190565A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric programmed cell death protein 1 receptor
WO2025191067A1 (en) 2024-03-13 2025-09-18 T-Knife Gmbh A chimeric transmembrane receptor comprising at least one t-cell immunoreceptor with ig and itim domains (tigit) polypeptide region, t-cells expressing the chimeric human tigit switch receptor, vectors with nucleic acids encoding for the tigit receptor, kits for preparing the t-cells, as well as corresponding pharmaceutical compositions and methods for treating a patient having a disease and for increasing cytotoxicity of a t-cell in adoptive cell therapy
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1812095A (en) 1994-02-23 1995-09-11 Akzo Nobel N.V. A t cell receptor sequence specifically associated with an immune disease
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
AU2018204891A1 (en) 2018-07-26
EP2951202A2 (en) 2015-12-09
US20150353622A1 (en) 2015-12-10
JP6639233B2 (ja) 2020-02-05
US20190375816A1 (en) 2019-12-12
US12338272B2 (en) 2025-06-24
SI2951202T1 (sl) 2020-08-31
JP2016505635A (ja) 2016-02-25
AU2014211454A1 (en) 2015-09-17
US10377808B2 (en) 2019-08-13
AU2018204891B2 (en) 2020-03-12
CN105377886A (zh) 2016-03-02
WO2014118236A8 (en) 2014-12-18
WO2014118236A3 (en) 2014-10-09
EP3747899A2 (en) 2020-12-09
PT2951202T (pt) 2020-07-07
WO2014118236A2 (en) 2014-08-07
HUE050390T2 (hu) 2020-11-30
EP2951202B1 (en) 2020-04-08
PL2951202T3 (pl) 2020-09-21
US20230025572A1 (en) 2023-01-26
AU2014211454B2 (en) 2018-04-05
CA2899679C (en) 2023-03-21
EP3747899A3 (en) 2021-02-24
CA2899679A1 (en) 2014-08-07
ES2804538T3 (es) 2021-02-08
CN105377886B (zh) 2020-07-28
HK1218551A1 (en) 2017-02-24
US11447536B2 (en) 2022-09-20

Similar Documents

Publication Publication Date Title
DK2951202T3 (da) Mage-a1-genkendende bindingsmolekyler med høj aviditet
DK2970464T3 (da) Anti-lag-3-bindende proteiner
GB201319161D0 (en) Multivalent antigen-binding protein molecules
IL240045A0 (en) Antigen-binding molecules activate bi-specific t cells
DK2951203T3 (da) Heterodimere proteiner
DK3736291T5 (da) Anti-FCRH5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
EP2957784A4 (en) SLIDING ELEMENT
EP2987933A4 (en) HINGE
DK3068800T3 (da) FcRn-specifikke antistoffer
IL240753B (en) Methods for purifying antibodies
EP3919896C0 (en) Two part assembly
DK3047163T3 (da) Lukkeelement
DK3065774T3 (da) Anti-CCL17-antistoffer
CL2014001444S1 (es) Clip
GB201302878D0 (en) Modified igG molecules
DK3080385T3 (da) Forbedret lukkeapparat
GB201307501D0 (en) Anti-fungal antibody molecules and uses thereof
EP3014533A4 (en) IMPACT-SAFE SIGNATURE
DE112014005946A5 (de) Verstellpumpe
CL2015002282S1 (es) Encendedor
ES1134036Y (es) Sacacorchos
FR3011538B3 (fr) Tire-bouchon
UA25234S (uk) Запальничка
UA28341S (uk) Вмістина